September 29, 2010


PARSIPPANY, NJ – September 29, 2010 – Ferring Pharmaceuticals Inc. has announced that EUFLEXXA ®(1% sodium hyaluronate), an injectable treatment for the pain of knee osteoarthritis, will serve as the presenting sponsor of the 2010 National Senior Games Championships and EUFLEXXA Hockey Classic in Rochester, NY.

The National Senior Games Championships and EUFLEXXA Hockey Classic is an annual event made up of athletes aged 50 and over who compete in ice hockey, pickle ball, and curling. The event is expected to draw over 300 athletes to the Rochester area from September 29 – October 4 and will take place across three different venues.

“We are excited to be part of such an amazing event,” said Lee Shea Betten, Product Manager for EUFLEXXA. “Our commitment to these athletes helps us to further emphasize that active aging is possible.”

Ferring has been working with the National Senior Games Association since 2007 and EUFLEXXA will also be a silver medal sponsor of the 2011 Summer National Senior Games in Houston, TX.

About the NSGA

NSGA is a multi-sport organizations council member of the United States Olympic Committee (USOC) and serves as the USOC’s official arm to the 50 and over population. The NSGA is a not-for-profit organization dedicated to promoting healthy lifestyles for adults 50 and over through education, fitness and sport. Through its programs, the NSGA assists adults in achieving greater value and quality in their lives by staying healthy, active and fit. NSGA thanks its corporate sponsors Humana, AstraZeneca, and Euflexxa. Go to for more information about NSGA and its programs.


EUFLEXXA® (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used in people who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.


You should not receive this product if you have had any previous allergic reaction to EUFLEXXA® or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or if you have skin disease or infection around the injection site.

EUFLEXXA® is only for injection into the knee performed by a qualified doctor. After you receive this injection you may need to avoid activities such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour). The safety and effectiveness of repeat treatment cycles of EUFLEXXA® have not been established. The safety and effectiveness of EUFLEXXA® have not been shown in people under 18 years of age.

Side effects sometimes seen when EUFLEXXA® is injected into the knee joint were pain, swelling, skin irritation, and tenderness and these were generally mild and did not last long

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of products in the U.S. market. They include: BRAVELLE® (urofollitropin for injection, purified), MENOPUR® (menotropins for injection, USP) and REPRONEX® (menotropins for injection, USP), NOVAREL® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, 100 mg, LYSTEDA ™ (tranexamic acid tablets), FIRMAGON® (degarelix for injection), PROSED® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA® (1% sodium hyaluronate).

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For more information, call 1-888-FERRING (1-888-337-7464) or visit

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, CLENPIQ, ENDOMETRIN, EUFLEXXA, FIRMAGON, MENOPUR, NOCDURNA, NOVAREL, and ZOMACTON are registered trademarks of Ferring B.V. INVOCELL is a registered trademark of INVO BioScience. ORTIKOS is a trademark of Sun Pharma Global FZE.

©2008-2020 Ferring Pharmaceuticals.  US-CORP-2000062